z-logo
Premium
Inhibition of matrix metalloproteinase‐2 secretion and invasion by human ovarian cancer cell line SK‐OV‐3 with lysine, proline, arginine, ascorbic acid and green tea extract
Author(s) -
Roomi M. Waheed,
Ivanov Vadim,
Kalinovsky Tatiana,
Niedzwiecki Aleksandra,
Rath Matthias
Publication year - 2006
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2006.00389.x
Subject(s) - ascorbic acid , arginine , medicine , matrix metalloproteinase , secretion , lysine , proline , biochemistry , cell culture , matrix (chemical analysis) , cancer research , amino acid , biology , food science , chemistry , genetics , chromatography
Aims:  Based on the poor prognosis associated with ovarian cancer and reported anticancer properties of specific nutrients, we investigated the effect of a nutrient mixture (NM) containing lysine, proline, arginine, ascorbic acid and epigallocatechin gallate on human ovarian cancer cells SK‐OV‐3 by measuring: cell proliferation, modulation of matrix metalloproteinase (MMP)‐2 and ‐9 expression, and cancer cell invasive potential. Methods:  Cell proliferation was evaluated by MTT assay, MMP activity by gelatinase zymography, and invasion through Matrigel. Results:  Human ovarian cancer cell growth was not significantly affected by the NM. Zymography demonstrated inhibition of MMP‐2 secretion in a dose‐dependent fashion with virtual total inhibition at 50 µg/mL NM concentration. Invasion of human ovarian cancer cells through Matrigel decreased in a dose‐dependent fashion, with 90% inhibition at 500 µg/mL NM and 100% inhibition at 1000 µg/mL NM ( P  < 0.0001). Conclusion:  The combination of lysine, proline, arginine, ascorbic acid and green tea extract tested inhibited critical steps in cancer development and spread, such as MMP expression and invasion, indicating its potential as a treatment modality against ovarian cancer.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here